Pentachloropseudilin

Pentachloropseudilin (Antibiotic A 15104 Y; PClP) is a reversible and allosteric potent inhibitor of Myo1s (class 1 myosins) with IC50s range from 1 to 5 μM for mammalian class-1 myosins and greater than 90 μM for class-2 and class-5 myosins. Pentachloropseudilin is a potent inhibitor of transforming growth factor-β (TGF-β) -stimulated signaling, with an IC50 of 0.1 to 0.2 μM for TGF-β[1][2].

Product Specifications

CAS Number

[69640-38-6]

Product Name Alternative

Antibiotic A 15104 Y; PClP

UNSPSC

12352005

Target

Myosin; TGF-β Receptor

Type

Reference compound

Related Pathways

Cytoskeleton; TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/pentachloropseudilin.html

Purity

98.88

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC1=C(C2=C(Cl)C(Cl)=C(Cl)N2)C=C(Cl)C=C1Cl

Molecular Formula

C10H4Cl5NO

Molecular Weight

331.41

References & Citations

[1]Chinthalapudi K, et al. Mechanism and specificity of pentachloropseudilin-mediated inhibition of myosin motor activity. J Biol Chem. 2011;286 (34) :29700-29708.|[2]Chung CL, et al. Pentachloropseudilin Inhibits Transforming Growth Factor-β (TGF-β) Activity by Accelerating Cell-Surface Type II TGF-β Receptor Turnover in Target Cells. Chembiochem. 2018;19 (8) :851-864. |[3]Cota Teixeira S, et al. Pentachloropseudilin Impairs Angiogenesis by Disrupting the Actin Cytoskeleton, Integrin Trafficking and the Cell Cycle. Chembiochem. 2019;20 (18) :2390-2401.